Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$8.01 USD
+0.14 (1.78%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.00 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
DCTH 8.01 +0.14(1.78%)
Will DCTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DCTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DCTH
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
DCTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?
Other News for DCTH
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits
Buy Rating Affirmed for Delcath Systems Amidst Strong Hepzato Launch and Promising Future Prospects
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)